Opes Wealth Management LLC Acquires 1,199 Shares of Eli Lilly and Company $LLY

Opes Wealth Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 355.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,536 shares of the company’s stock after acquiring an additional 1,199 shares during the quarter. Opes Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,197,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of LLY. WestEnd Advisors LLC grew its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at about $27,000. Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the last quarter. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the last quarter. Finally, IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the second quarter valued at about $35,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. UBS Group reduced their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Berenberg Bank restated a “hold” rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Stock Up 1.1%

Eli Lilly and Company stock opened at $820.97 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $777.01 billion, a P/E ratio of 53.66, a PEG ratio of 1.16 and a beta of 0.47. The stock has a 50-day simple moving average of $765.52 and a 200-day simple moving average of $767.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.